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Abstract
Doxorubicin (DOX) is a widely used chemotherapeutic anticancer drug. Its intrinsic fluores-
cence properties enable investigation of tumor response, drug distribution and metabolism.
First phantom studies in vitro showed optoacoustic property of DOX. We therefore aimed to
further investigate the optoacoustic properties of DOX in biological tissue in order to explore
its potential as theranostic agent. We analysed doxorubicin hydrochloride (Dox�HCl) and
liposomal encapsulated doxorubicin hydrochloride (Dox�Lipo), two common drugs for anti-
cancer treatment in clinical medicine. Optoacoustic measurements revealed a strong signal
of both doxorubicin substrates at 488 nm excitation wavelength. Post mortem analysis of
intra-tumoral injections of DOX revealed a detectable optoacoustic signal even at three
days after the injection. We thereby demonstrate the general feasibility of doxorubicin detec-
tion in biological tissue by means of optoacoustic tomography, which could be applied for
high resolution imaging at mesoscopic depths dictated by effective penetration of visible
light into the biological tissues.
Introduction
Doxorubicin hydrochloride, an anthracycline antibiotic, is one of the most commonly used
anti-cancer therapeutics. The small amphiphilic and amphoteric molecule enters the cell by
diffusion and subsequently exhibits cytotoxic properties. On the one hand, Dox�HCl interca-
lates into the DNA causing cell cycle arrest, on the other hand Dox�HCl inhibits Topoisomer-
ase II and thereby induces cell death [1]. Additionally, the generation of reactive oxygen
species leads to mitochondrial dysfunction, which, as a main side effect causes cardiotoxicity.
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Fluorescence characteristics of Dox�HCl have been intensively investigated as they allow
detection by various microscopic and macroscopic technologies [2]. Owing to its fluorescent
features, Dox�HCl is easily detectable and also quantifiable by spectrophotometry [3]. In
clinical and preclinical research, optical imaging is a widespread tool to monitor tumor behav-
iour during therapy [4]. So far, intravital microscopy and flow cytometry are used to follow
Dox�HCl uptake within living cells [5, 6]. Similarly, ex vivo experiments in mice using fluores-
cence-based optical imaging systems have been reported [7]. Several analyses concerning fluo-
rescence imaging and spectral shifts of incorporated Dox�HCl have been published so far [8].
Stucke-Ring et al. reported that intravenous injection of Dox�HCl led to a fast accumulation of
Dox�HCl within the tumor cells with a fluorescent peak 6 hours after injection and fluores-
cence detection even ten days later [9]. Thus, the fluorescent properties of Doxorubicin are
beneficial to investigate drug distribution and pharmacokinetics after drug application in vivo.
However, fluorescence imaging is limited by poor tissue penetration of NIR light and
decreased spatial resolution due to scattering and diffusion.
Optoacoustic imaging instead benefits from high contrast and spectral specificity of optical
imaging in combination with the increased imaging depth and spatial resolution of ultrasound
imaging. Optoacoustic imaging detects ultrasound waves produced by the absorption of pulsed
near-infrared light (NIR) [10]. Multispectral optoacoustic tomography is able to visualize opti-
cal contrast of tissues or certain molecules without the use of exogenous contrast agents [11].
Highly perfused tumors are detectable and distinguishable from microenvironment by the dif-
ferent appearance of their neovasculature. In addition, differential spectral absorption charac-
teristics can be used to detect multiple reporters simultaneously. Endogenous chromophores,
which are detectable by optoacoustic imaging, include haemoglobin, melanin and lipids.
The aim of this study was to elucidate the intrinsic optoacoustic properties of DOX and
evaluate optoacoustic detection of doxorubicin experimentally in tumors post mortem. We
hypothesize that due to its intrinsic fluorescent properties, doxorubicin will generate a detect-
able optoacoustic signal which can be spatially resolved and thus reveal the biodistribution of
the drug after injection into experimental tumors. This may open new opportunities to investi-
gate drug distribution and mechanistic effects such as interaction between the drug and adja-
cent tumor tissue in proximity to the drug after in vivo application.
Material and methods
Animals
Procedures involving animals and their care were conducted in conformity with national and
international guidelines (EU 2010/63) with approval from the local authority (Government of
Upper Bavaria) and supervised by the Animal Care and Use Committee of Klinikum rechts
der Isar (Munich Germany). Animals were housed in standard animal rooms (12 h light/dark
cycle, 50–60% humidity, 18˚C-23˚C temperature, bedding material) in individually ventilated
cage systems (IVC Techniplast) under specific pathogen-free conditions with free access to
water and standard laboratory chow ad libitum. Post mortem excised tumors from two female
C57Bl/6-albino mice (8–12 week-old, Charles River Laboratories, Europe) used for the pilot
study were used in terms of the 3Rs guiding principles. One mouse without doxorubicin injec-
tion was used as negative control.
In vitro experiments
Doxorubicin hydrochloride (Dox�HCl) (Teva, UK) and PEGylated, liposomal encapsulated
Doxorubicin (Dox�Lipo) (Caelyx, EurimPharm, Germany) were supplied by the pharmacy of
Klinikum rechts der Isar. Negative side effects of Doxorubicin hydrochloride are preventable
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by encapsulation of Dox�HCl in PEGylated liposomes. The altered pharmacokinetic profile of
Dox�Lipo initiates a longer circulation rate and a reduced volume of distribution which makes
the tumor more targetable during therapy [7, 12]. For the spectrophotometric study in vitro
46 μM Dox�HCl and Dox�Lipo were used. Spectrophotometric measurements of Dox�HCl was
carried out at room temperature. Excitation profiles were measured in the spectral range from
400 to 800 nm. Optoacoustic profiles were performed using 1 mM Dox�HCl and Dox�Lipo in
the imaging set up described in the section "Optoacoustic imaging".
Ex vivo experiments
We used the carcass of one CD-1 nude mouse (governmental approved vivarium of Helmholtz
Zentrum Neuherberg) for post mortem s.c. injection of 1 mM, 0,1 mM and 0,01 mM Dox�HCl
and Dox�Lipo in 50 μl phenol-red free matrigel (Corning). Dox�HCl and Dox�Lipo spots were
injected separately s.c. in the back of the mouse (Fig 1B). Subsequently, optoacoustic imaging
ex vivo was performed. Images of the carcass without DOX injection served as negative
control.
In vivo experiments
Briefly, 1x10^6 EG7 murine tumor cells (American Type Culture Collection, Manassas,
USA), which are known to be Doxorubicin sensitive [13], were inoculated s.c. into the
Fig 1. Optoacoustic properties of DOX in vitro. (A) Optoacoustic measurement of Dox�HCl and Dox�Lipo. Both formulations show a maximum peak at 480/490
nm. (B) Spectrophotometric assessment of Dox�HCl revealed a peak fluorescence at 480/490 nm. (C) Detection limit in vitro of Dox�HCl (lower curve) and Dox�Lipo
(upper curve). For both formulations the limit was determined at 0.01 mM. Experiments were done in triplets.
https://doi.org/10.1371/journal.pone.0217576.g001
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neck of two female C57Bl/6-albino mice using standard procedures and isoflurane anesthe-
sia (1.8% Isoflurane with medical O2). Animals did not show any severe signs of illness
following tumor formation. 5 mg Dox�Lipo per kg body weigh was injected once intratumo-
rally. Tumor volume was measured with a caliper and tumor sizes calculated using the for-
mula: tumor vol [mm^3] = 0,5 x (length x width^2). The animals were euthanized at
indicated time points (4 hours and 72 hours) by an injectable anesthetic overdose of keta-
mine-xylazine. Tumor volume was 31 mm^3 (4 hours) and 45 mm^3 (72 hours) and did not
exceed the maximum tumor volume (500 mm^3). Animal protocol defined a weight loss of
more than 15% compared to the weight at tumor inoculation as threshold for maximum
weight loss allowed. Animals did not lose weight over time (start: 22.8 g and 24.8 g, stop:
22.7 g and 24.2 g) and no adverse events took place. Tumors were not ulcerated or blistered.
No animal died due to experimental procedures or humane endpoints. Tumors were excised
post mortem, washed with 1x PBS to remove excess blood and fixated in 4% neutral-buffered
formalin. Until post mortem optoacoustic imaging the tumors were stored in 70% Ethanol
at 4˚C.
Optoacoustic imaging
Optoacoustic imaging was performed by a custom-made spherical concave transducer array
consisting of 512 ultrasound sensing elements with 5 MHz central frequency and approxi-
mately 100% bandwidth [14]. The spherical active surface of the array had a radius of 40 mm
and covered an angle of 140˚ (solid angle 1.31π). During the measurements, the array was ori-
ented upwards and the volume enclosed with the hemispherical cup was filled with agar to
guarantee acoustic coupling and to further serve as a solid platform. The specimen lay in a
supine position on top of the agar surface and optoacoustic excitation was performed with an
optical parametric oscillator (OPO)-based laser guided via a fiber bundle through a central
cylindrical cavity of the array. The wavelength of the laser was scanned between 440 and 640
nm (20 nm step), while the pulse repetition frequency (PRF) was set to 10 Hz. For each laser
pulse, a set of 512 signals corresponding to each array element were simultaneously collected
with a custom-made data acquisition system.
The measurement of DOX signal in tumor tissue ex vivo facilitated the quantification of
optoacoustic signals generated by DOX which otherwise would be distorted by strong attenua-
tion in the living animal and furthermore allowed a proper positioning of the tumor in the
imaging system.
Image reconstruction and spectral unmixing
Optoacoustic reconstruction of the acquired frames was performed off-line. For this purpose,
the acquired raw signals were first deconvolved with the measured electrical impulse response
of the detection transducer elements. The signals were then band-pass filtered with cut-off fre-
quencies between 0.1 and 7 MHz. A three-dimensional model-based reconstruction algorithm
was employed to render three dimensional images of the optical absorption distribution [15].
Specifically, a three-dimensional volume of 12×12×12 mm3 containing 120×120×120 voxels
was reconstructed for each time instant.
The images reconstructed at multiple wavelengths were further processed to spectrally
unmix the distribution of DOX within the tissue. For this, a standard linear model was used
assuming that the spectral profile at any pixel is a linear combination of the optical absorbing
spectra of the substances present in tissue [16].
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Results
In clinical oncology doxorubicin (DOX) is used as the pure compound doxorubicin hydro-
chloride (Dox�HCl) or encapsulated in liposomes (Dox�Lipo). We investigated the optoacous-
tic properties of both formulations first in vitro. 1 mM of Dox�HCl and 1 mM of Dox�Lipo
were measured in an optoacoustic set up. Both formulations presented a peak at 480/490 nm
(Fig 1A) which was in accordance with the literature [17].
We also verified the excitation profile of Dox�HCl (Fig 1B) which was in agreement with
the literature. Next, we investigated the detection limit of the optoacoustic system for Dox�HCl
and Dox�Lipo (Fig 1C). Both formulations decreased from 0.1 mM to 0.001 mM with a detec-
tion limit at 0.01 mM for Dox�HCl and Dox�Lipo (Fig 1C). To detect the sensitivity limit of
optoacoustic imaging in a biological set up ex vivo, we injected 1 mM, 0,1 mM and 0,01 mM
Dox�HCl and Dox�Lipo s.c. on the back of a mouse carcass (Fig 2A) and the optoacoustic signal
was recorded at multiple wavelengths (440 nm to 640 nm).
Images obtained before DOX injection served as negative control (Fig 2H). Small green
areas in the unmixed image associates to cross talk errors in the unmixing procedure and were
considered as background signal. Images were spectrally unmixed and signal intensity pseudo-
colored for better representation. The optoacoustic image at 600 nm (for anatomical features)
is shown along with the unmixed signal of DOX in green to blue color bar (Fig 2B–2G).
Dox�HCl exhibited good optoacoustic signal at the highest concentration used (1 mM) (Fig
2B). At a concentration of 0,1 mM DOX could still be detected (Fig 2C), with no signal
detectable at 0,01 mM (Fig 2D). Similar results were found for Dox�Lipo, which rendered the
strongest signal at 1 mM solution (Fig 2E) compared to 0,1 mM (Fig 2F) and 0,01 mM (Fig
2G). Tissue without any Doxorubicin content (negative control, Fig 2H) revealed minor resid-
ual contrast in the doxorubicin wavelength range, which is attributed to cross-talk of the
unmixing algorithm. The concentration of 0.1 mM represents the detection limit of the ex vivo
experiment.
For the optoacoustic detection of DOX in biological tissue we analyzed post mortem two
tumors which were injected i.t. with 3.45 mM Dox�Lipo. Tumors were excised 4 hours (Fig
3A) and 72 hours (Fig 3B) after DOX application and formalin-fixed prior to imaging.
Since hemoglobin and deoxygenated hemoglobin are major absorbers in biological tissues
with peak absorption close to that of DOX, tumors were washed to remove excess blood. After
4 hours Dox�Lipo was detected at and circular around the injection site (Fig 3A). Even 72
hours after Dox�Lipo application, DOX was still detectable (Fig 3B). Difference in signal inten-
sity of the optoacoustic doxorubicin signal between 4h and 72h post injection was 42.5%.
Discussion
Herein we report for the first time the investigation of the optoacoustic properties of doxorubi-
cin in biological environment and thereby the applicability of using doxorubicin as a theranos-
tic anti-cancer agent in combination with molecular optoacoustic imaging.
Due to its intrinsic fluorescent properties, favourable biodistribution, metabolism and drug
action, doxorubicin has been examined in vivo and ex vivo by various optical techniques
including multiphoton imaging [18, 19]. Similarly, fluorescence emitted by doxorubicin can
be quantified ex vivo in fluorescence microscopy or spectrofluorometric analysis [9]. First
optoacoustic investigations were reported in gelatine phantoms and in aqueous solution,
showing the basic feasibility to detect doxorubicin with this technique [20]. These theranostic
properties can provide novel insights into the interaction between tumor cells and doxorubi-
cin, one of the most frequently used anti-cancer agents.
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Fig 2. Optoacoustic properties of DOX ex vivo. (A) Schematic overview of the ex vivo optoacoustic imaging analysis
of 1 mM (top), 0,1 mM (center) and 0,01 mM (bottom) of Dox�Lipo (right panel) and Dox�HCl (left panel). (B-G)
Optoacoustic images of Dox�HCl (B-D) and Dox�Lipo (E-G) in 50 μl matrigel. (B) 1 mM Dox�HCl, (C) 0,1 mM
Dox�HCl, (D) 0,01 mM Dox�HCl, (E) 1 mM Dox�Lipo, (F) 0,1 mM Dox�Lipo, (G) 0,01 mM Dox�Lipo, (H) no
doxorubicin (control). Signal intensity of the unmixed DOX signal is pseudo-colored in blue/green, signal intensity of
the optoacoustic signal at 600 nm is pseudo-colored in red/yellow. Scale bar = 5 mm.
https://doi.org/10.1371/journal.pone.0217576.g002
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Fluorescence imaging in general is limited to investigation of superficial tissue due to dif-
fuse attenuation and scattering of light [21]. Optoacoustic imaging combines imaging of opti-
cal contrast with ultrasound resolution. Besides macroscopic imaging of cancer biology in vivo
in preclinical models of disease, novel optoacoustic systems are operating at the mesoscopic or
microscopic scale [22, 23], which permit studying direct interactions between tumor cells, the
tumor microenvironment and tumor vasculature. Label-free detection using intrinsic signal-
ling properties is favourable over cumbersome additional labelling or additional injection of a
specific imaging probe. A first label-free imaging study with breast cancer patients demon-
strated the general applicability of optoacoustic imaging in the clinics. The high spatial resolu-
tion and the differentiation of oxygenated and deoxygenated haemoglobin can visualize
dedicated tumor characteristics and discriminate tumorous from non-tumorous tissue
[24, 25].
Combining the potential of optoacoustic imaging with the ability to visualize Doxorubicin
by optoacoustic imaging can potentially allow to monitor drug distribution and metabolism in
vivo following therapy in the preclinical setting.
Also, chemical modification of chemotherapeutics by adding signalling moieties, such as
quantum dots or nanoparticles, potentially modifies biodistribution, targeting behaviour and
anti-tumor efficacy. We therefore investigated the intrinsic optoacoustic properties of doxoru-
bicin both in a phantom setup as well as in a murine tumor model to elucidate the possibility
of preclinical optoacoustic imaging of therapeutic doses of doxorubicin. A first study doxoru-
bicin containing gel phantoms revealed that concentrations down to 0.5 mg/ml can generate
an optoacoustic signal, which however was not further evaluated in biological tissue [26].
Using optoacoustic imaging, we are able to show that DOX can be detected for up to 72
hours post injection, Increased permeability of the tumor vasculature allows liposomes to pass
through the leaky vessels and to accumulate within the tumor tissue. In addition, longer
plasma concentration and a lower clearance rate in combination with a longer half-life [27]
characterizes liposomal encapsulated Dox�HCl compared to free Dox�HCl. We attribute the
Fig 3. Optoacoustic detection of DOX in tumor tissue. Detection of 3.45 mM Dox�Lipo 4 hours (A) and 72 hours
(B) after i.t. application. For both tumors the top and the lateral maximum intensity projections are shown. Unmixed
optoacoustic signal of DOX is pseudo-coloured in blue/green. Scale bar = 2 mm.
https://doi.org/10.1371/journal.pone.0217576.g003
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prolonged detection of Dox�Lipo even 72 hours after injection to the altered pharmacokinetic
profile. Previous in vitro experiments described the time dependence of DOX accumulation in
melanoma cells [28]. Cells were incubated in 5μM DOX and 10 and 30 minutes later the fluo-
rescence intensities of 0.06 μM and 0.2μM DOX out of 106 cells were detected. Those experi-
ments reveal the potential of cellular DOX uptake shortly after drug administration. Elevated
drug concentration and increased time span suggest higher intracellular uptake and accumula-
tion of Dox�Lipo due to its altered pharmacokinetic properties. Of note, DOX uptake differs
considerably between different cancer cell lines and cancer types [29].
Since DOX has absorption spectrum characteristics close to those of haemoglobin and
deoxyhaemoglobin, accurate unmixing algorithms have to be applied for the analysis of in
vivo data. Of note, the range of wavelengths where doxorubicin is able to absorb energy for
acoustic conversion is far below the near infrared range (< 550 nm) and outside the biologi-
cal window, restricting in vivo detection in deeper tissue. Micro- and meso-scopic tech-
niques operating at superficial depths, such as raster scanning optoacoustic mesoscopy
(RSOM), however could be applied to study the biodistribution of DOX in vivo and ex
vivo with improved spatial resolution compared to conventional fluorescence imaging
[30]. Also, dedicated methods like intravascular optoacoustic imaging or optoacoustic
endoscopy may allow visualization of perivascular doxorubicin distribution in affected
cancerous tissue [31, 32]. A proper calibration of the detected optoacoustic signal as a func-
tion of the concentration of DOX could serve to estimate the concentration of DOX in blood
or in tissues.
Besides technological challenges it remains to be studied how the optoacoustic signal of the
doxorubicin distribution in tumor tissue as detected by optoacoustic imaging correlates with
the acute cytotoxic drug effects. As the kinetics of doxorubicin accumulation in tumors after
intravenous [33] and intratumoural injection [34] have been investigated in detail, a follow-up
study of the mechanistic drug effects in correlation to to optoacoustic signal has to prove if
optoacoustic is indeed capable of monitoring anti-cancer drug effects.
For the presented experiments doxorubicin was applied according to concentrations
described in the literature. Self-quenching of Dox may be an issue and has to be considered for
signal quantification. Additional experiments with intravenous doxorubicin injection are
needed to further assess detectability by means of optoacoustic imaging.
Conclusion
In summary, we have shown the feasibility to map the presence of doxorubicin in biological
environment of subcutaneous murine tumor xenografts by multispectral optoacoustic tomog-
raphy. Different amounts of doxorubicin hydrochloride and liposomal encapsulated doxorubi-
cin can be detected and quantified using a dedicated small animal optoacoustic imaging
system. The low penetration depth of light in the used spectral range capable of effective excita-
tion of doxorubicin, however, limits the applicability of this approach. New technologies like
optoacoustic endoscopy can overcome the restriction of penetration depth in luminal biologi-
cal tissue and promote its advancement towards clinical application—combining rich optical
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